Paul Tudor Jones’s Abeona Therapeutics ABEO Stock Holding History

Paul Tudor Jones’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.23M	Buy	+360,800	New	+$1.98M	﹤0.01%	1873
2019 Q2	–	Sell	-474	Closed	-$87K	–	1067
2019 Q1	$87K	Buy	+474	New	+$84.8K	﹤0.01%	1042
2018 Q1	–	Sell	-484	Closed	-$192K	–	970
2017 Q4	$192K	Sell	484 -800	-62%	-$331K	﹤0.01%	968
2017 Q3	$547K	Buy	+1,284	New	+$345K	0.01%	604
2017 Q2	–	Sell	-1,340	Closed	-$168K	–	999
2017 Q1	$168K	Hold	1,340	–	–	0.01%	1255
2016 Q4	$162K	Buy	+1,340	New	+$210K	﹤0.01%	1258

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OIA

OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Paul Tudor Jones's ABEO Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in Abeona Therapeutics (ABEO) in Q2 2026: 360,800 shares worth $2.23M. The stake represents ﹤0.01% of the portfolio and ranks #1873 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in ABEO as recently as Q1 2019.

Paul Tudor Jones first reported a position in ABEO in Q4 2016 and has held it in 6 quarters since. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

Paul Tudor Jones held 360,800 shares of Abeona Therapeutics worth $2.23M as of Q2 2026.
Abeona Therapeutics was a new Paul Tudor Jones position in Q2 2026.
Abeona Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1873 holding.
Paul Tudor Jones first reported a position in Abeona Therapeutics in Q4 2016 and has held it in 6 quarters since.
126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.